预测房颤合并缺血性卒中患者的大出血风险
本研究基于RE-LY试验中3623例有短暂性脑缺血发作或卒中史的房颤患者,验证HEMORR2HAGES、Shireman、HAS-BLED、ATRIA和ORBIT评分对大出血的预测性能。随访6922人年期间266例发生大出血(3.8/100人年),C统计量0.62(Shireman)至0.67(ATRIA),ATRIA校准差,其他模型中等。无论出血风险类别,华法林减少复发性缺血性卒中的获益大于大出血风险增加。
要点
- 出血风险评分在房颤合并脑缺血患者中区分度中等,C统计量0.62-0.67。
- ATRIA校准差,其他模型校准中等。
- 出血风险评分不能指导口服抗凝治疗决策,但可识别可纠正的出血危险因素。
核心结论
- 房颤合并脑缺血患者大出血预测模型性能中等,与仅房颤患者相当。
- 出血风险评分不能指导口服抗凝治疗决策,但可能有助于识别可纠正的出血危险因素。
- ORBIT评分基于有限易得变量且表现合理,临床实用性可能最佳。
研究设计与样本
- 分析RE-LY试验中3623例有短暂性脑缺血发作或卒中史的房颤患者。
- 评估HEMORR2HAGES、Shireman、HAS-BLED、ATRIA和ORBIT评分的C统计量和校准图。
- 通过比较华法林减少缺血性卒中与大出血风险增加探索净获益。
主要发现
- 随访6922人年期间266例发生大出血(3.8/100人年)。
- C统计量范围0.62(Shireman)至0.67(ATRIA)。
- ATRIA校准差,其他模型校准中等。
- 无论出血风险类别,华法林减少复发性缺血性卒中的获益大于大出血风险增加。
关键数值与推荐
- 大出血发生率3.8/100人年。
- C统计量:Shireman 0.62,ATRIA 0.67。
- ATRIA校准差,其他模型校准中等。
临床怎么用
- 出血风险评分不应单独用于决定是否启动口服抗凝治疗。
- 可使用出血风险评分识别和纠正可改变的出血危险因素。
- ORBIT评分因变量易得且性能合理,可能更适合临床使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Performance of risk scores for major bleeding in patients with atrial fibrillation and a previous transient ischemic attack or ischemic stroke is not well established. We aimed to validate risk scores for major bleeding in patients with atrial fibrillation treated with oral anticoagulants after cerebral ischemia and explore the net benefit of oral anticoagulants among bleeding risk categories. METHODS: We analyzed 3623 patients with a history of transient ischemic attack or stroke included in the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). We assessed performance of HEMORR2HAGES (hepatic or renal disease, ethanol abuse, malignancy, older age, reduced platelet count or function, hypertension [uncontrolled], anemia, genetic factors, excessive fall risk, and stroke), Shireman, HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol concomitantly), ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation), and ORBIT scores (older age, reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) with C statistics and calibration plots. Net benefit of oral anticoagulants was explored by comparing risk reduction in ischemic stroke with risk increase in major bleedings on warfarin. RESULTS: During 6922 person-years of follow-up, 266 patients experienced a major bleed (3.8 per 100 person-years). C statistics ranged from 0.62 (Shireman) to 0.67 (ATRIA). Calibration was poor for ATRIA and moderate for other models. The reduction in recurrent ischemic strokes on warfarin was larger than the increase in major bleeding risk, irrespective of bleeding risk category. CONCLUSIONS: Performance of prediction models for major bleeding in patients with cerebral ischemia and atrial fibrillation is modest but comparable with performance in patients with only atrial fibrillation. Bleeding risk scores cannot guide treatment decisions for oral anticoagulants but may still be useful to identify modifiable risk factors for bleeding. Clinical usefulness may be best for ORBIT, which is based on a limited number of easily obtainable variables and showed reasonable performance.
引用
- Hilkens NA, Algra A, Greving JP, et al. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation. Stroke. 2017. PMID: 28931618. doi:10.1161/STROKEAHA.117.019183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。